In this video, Motley Fool health-care analyst David Williamson looks at the newest hepatitis C partnership, this time between small biotech Idenix and big pharma Johnson & Johnson. The race is on to create a cure using a combination of the next generation of interferon-free drugs, and the companies without all the parts for a viable cocktail are frantically teaming up to gain traction before it is too late. Watch to find out what this newest collaboration means for investors in both companies.
